Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $10 from $8 and keeps a Buy rating on the shares following Eton’s acquisition of pediatric endocrinology drug Increlex from Ipsen (IPSEY). The firm says this move will be highly accretive to the company, and thinks it adds $10M in EBITDA in 2025 at current Increlex revenue levels of $19M, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON: